T. Sarosiek

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
T Sarosiek, T. Sarosiek, Tomasz Sarosiek
Publication record
70 papers · 1,174 citations · H-index 17

PAPERS

Pelvic splenosis infiltrating the uterus and ovary.
20250 citationsauthor #5
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
20245 citationsauthor #16
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer
20239 citationsauthor #14
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
202331 citationsauthor #25
Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer
20220 citationsauthor #16
IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study
20223 citationsauthor #16
Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
20221 citationsauthor #16
Constitutional microsatellite instability, genotype, and phenotype correlations in Constitutional Mismatch Repair Deficiency.
202225 citationsauthor #37
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency
2022108 citationsauthor #54
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
20221 citationsauthor #6
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency
20220 citationsauthor #54
Mutation and Microsatellite Burden Predict Response to PD-1 Inhibition in Children with Germline DNA Replication Repair Deficiency
20212 citationsauthor #47
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
202163 citationsauthor #49
Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency
202116 citationsauthor #7
Post-traumatic growth among gastrointestinal oncological patients: the perspective of Stevan Hobfoll’s conservation of resources theory
20202 citationsauthor #3
Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade
202020 citationsauthor #23
3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting
20191 citationsauthor #4
A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC).
20181 citationsauthor #5
Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB.
20182 citationsauthor #3
[Duodenal adenocarcinoma - a case report].
20180 citationsauthor #2
Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.
20182 citationsauthor #6
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
201865 citationsauthor #8
[Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
20186 citationsauthor #1
[Trastuzumab and its biosimilars].
201812 citationsauthor #1
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
201874 citationsauthor #9
Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1).
20170 citationsauthor #5
698P A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB.
20173 citationsauthor #3
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.
2017136 citationsauthor #5
MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (PT026).
20170 citationsauthor #4
153PDOne-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
20179 citationsauthor #9
1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
201737 citationsauthor #4
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
201720 citationsauthor #7
[Systemic treatment of early breast cancer - current state of knowledge after the conference St Gallen 2017].
20179 citationsauthor #1
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
201648 citationsauthor #5
Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.
20163 citationsauthor #7
O-027A pivotal phase 3 trial of MABp1 in advanced colorectal cancer
20163 citationsauthor #5
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
201512 citationsauthor #2
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
201415 citationsauthor #6
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
2014235 citationsauthor #7
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
201425 citationsauthor #2
Proceedings in penile cancer
20141 citationsauthor #3
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
201431 citationsauthor #6
Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron
20132 citationsauthor #8
Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)
20122 citationsauthor #2
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).
20116 citationsauthor #2
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results.
20113 citationsauthor #2
Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC).
20113 citationsauthor #8
OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer.
20110 citationsauthor #3
How can we help patients with refractory chronic graft versus host disease- single centre experience.
20095 citationsauthor #3
Prevention of cytomegalovirus reactivaction after allogenic hematopoietic stem cell transplantation with valganciclovir: single center experience.
20082 citationsauthor #3
[Nephrotic syndrome in the course of primitive neuroectodermal tumor--case report].
20080 citationsauthor #2
Prevention of Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation with Valganciclovir: Single Center Experience
20082 citationsauthor #3
Nutritional assessment during allogeneic hematopoietic stem cell transplantation: single centre experience.
20076 citationsauthor #3
Which parameters of nutritional status should we choose for nutritional assessment during hematopoietic stem cell transplantation?
200719 citationsauthor #3
Biochemical indices for the assessment of nutritional status during hematopoietic stem cell transplantation: are they worth using? A single center experience
200730 citationsauthor #3
Multimodality treatment of germ cell cancer patients who had progression or relapse after high dose chemotherapy and autologous bone marrow transplantation.
20070 citationsauthor #1
Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
200715 citationsauthor #2
Autologous hematopoietic cell transplantation in adult patients with germ cell tumors and soft tissue sarcomas
20061 citationsauthor #2
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
200613 citationsauthor #2
Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
200510 citationsauthor #3
CVD BIO biochemotherapy of metastatic melanoma - one center clinical experience.
20040 citationsauthor #3
Role of hematopoietic stem cell transplantation and donor lymphocyte infusion in the treatment of metastatic renal cell carcinoma
20040 citationsauthor #6
Ifosfamide in the treatment of childhood lymphomas
20040 citationsauthor #3
Ifosfamide in the treatment of non-small cell lung cancer
20041 citationsauthor #2
CVD BIO biochemotherapy of metastatic melanoma - one center clinical experience
20040 citationsauthor #3
Biochemotherapy of mestastic melanoma – clinical experience and perspective analysis
20030 citationsauthor #5
Fotemustine in palliative treatment of metastatic cutaneous and ocular melanoma – clinical experience and preliminary results
20030 citationsauthor #6
High-dose chemotherapy of germ-cell tumors - is it the end of the road?
20030 citationsauthor #5
Hepatic arterial infusion chemotherapy for hepatic cancer end metastases – complications and technical limitations
20030 citationsauthor #10
Antisense therapy in cancer.
200023 citationsauthor #3

TIMELINE

2000 23 citations

2003 0 citations

2004 1 citations

2005 10 citations

2006 14 citations

2007 70 citations

2008 4 citations

2009 5 citations

2011 12 citations

2012 2 citations

2013 2 citations

2014 307 citations

2015 12 citations

2016 54 citations

2017 214 citations

2018 162 citations

2019 1 citations

2020 22 citations

2021 81 citations

2022 138 citations

2023 40 citations

2024 5 citations

2025 0 citations

T. Sarosiek

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT